PMID- 37349983
OWN - NLM
STAT- MEDLINE
DCOM- 20230905
LR  - 20230905
IS  - 1744-9987 (Electronic)
IS  - 1744-9979 (Linking)
VI  - 27
IP  - 5
DP  - 2023 Oct
TI  - Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: 
      A systematic review and meta-analysis of randomized placebo-controlled trials.
PG  - 839-847
LID - 10.1111/1744-9987.14028 [doi]
AB  - BACKGROUND: The effects of tenapanor in reducing serum phosphorus in hemodialysis 
      patients with hyperphosphatemia are uncertain and no relevant meta-analysis has 
      been conducted. We performed a meta-analysis of randomized placebo-controlled 
      trials to evaluate the efficacy and safety of tenapanor. METHODS: All randomized 
      controlled trials of tenapanor were searched up to 1 August 2022. The primary 
      endpoint was the change in serum phosphorus level from baseline with tenapanor 
      and placebo. Data on drug-related adverse events (AEs), gastrointestinal AEs and 
      diarrhea were collected to determine the safety of tenapanor. RESULTS: There were 
      533 patients throughout five trials that were eligible. Tenapanor significantly 
      lowered blood phosphorus level by 1.79 mg/dl in the mean difference than the 
      placebo. Diarrhea, gastrointestinal AEs, and drug-related AEs were more severe 
      than placebo. CONCLUSIONS: This meta-analysis showed that although drug side 
      effects were common, tenapanor significantly reduced serum phosphorus level in 
      hemodialysis patients.
CI  - (c) 2023 International Society for Apheresis and Japanese Society for Apheresis.
FAU - Luo, Houli
AU  - Luo H
AD  - Department of Radiology, Cheng du First People's Hospital, Chengdu, Sichuan, 
      China.
FAU - Feng, Jian
AU  - Feng J
AD  - Department of Critical Care Medicine, The General Hospital of Western Theater 
      Command, Chengdu, Sichuan, China.
FAU - Zhang, Yanbiao
AU  - Zhang Y
AD  - Department of Burn and Plastic, The General Hospital of Western Theater Command, 
      Chengdu, Sichuan, China.
FAU - Wang, Jie
AU  - Wang J
AD  - Department of Critical Care Medicine, The General Hospital of Western Theater 
      Command, Chengdu, Sichuan, China.
FAU - Xue, Gang
AU  - Xue G
AD  - Department of Burn and Plastic, The General Hospital of Western Theater Command, 
      Chengdu, Sichuan, China.
FAU - Huang, Xi
AU  - Huang X
AD  - Department of Burn and Plastic, The General Hospital of Western Theater Command, 
      Chengdu, Sichuan, China.
FAU - You, Shuang
AU  - You S
AD  - Department of Burn and Plastic, The General Hospital of Western Theater Command, 
      Chengdu, Sichuan, China.
FAU - Dong, Hongfei
AU  - Dong H
AD  - Department of Burn and Plastic, The General Hospital of Western Theater Command, 
      Chengdu, Sichuan, China.
FAU - Li, Lingfan
AU  - Li L
AD  - Department of Burn and Plastic, The General Hospital of Western Theater Command, 
      Chengdu, Sichuan, China.
FAU - Li, Juncheng
AU  - Li J
AD  - Department of Burn and Plastic, The General Hospital of Western Theater Command, 
      Chengdu, Sichuan, China.
FAU - Xiao, Hualin
AU  - Xiao H
AD  - Department of Burn and Plastic, The General Hospital of Western Theater Command, 
      Chengdu, Sichuan, China.
FAU - Ai, Xiang
AU  - Ai X
AD  - Department of Burn and Plastic, The General Hospital of Western Theater Command, 
      Chengdu, Sichuan, China.
FAU - Li, Xianhui
AU  - Li X
AD  - Department of Burn and Plastic, The General Hospital of Western Theater Command, 
      Chengdu, Sichuan, China.
FAU - Huang, Bo
AU  - Huang B
AUID- ORCID: 0000-0001-7937-9532
AD  - Department of Burn and Plastic, The General Hospital of Western Theater Command, 
      Chengdu, Sichuan, China.
LA  - eng
GR  - 2021-XAYG-B19/The General Hospital of Western Theater Command, The Military 
      Medical Research Program/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230622
PL  - Australia
TA  - Ther Apher Dial
JT  - Therapeutic apheresis and dialysis : official peer-reviewed journal of the 
      International Society for Apheresis, the Japanese Society for Apheresis, the 
      Japanese Society for Dialysis Therapy
JID - 101181252
RN  - WYD79216A6 (tenapanor)
RN  - 27YLU75U4W (Phosphorus)
SB  - IM
MH  - Humans
MH  - *Hyperphosphatemia/drug therapy/etiology
MH  - Double-Blind Method
MH  - Renal Dialysis/adverse effects
MH  - Diarrhea/etiology
MH  - Phosphorus
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Tenapanor
OT  - chronic kidney disease
OT  - hemodialysis
OT  - hyperphosphatemia
OT  - meta-analysis
OT  - placebo-controlled trials
EDAT- 2023/06/23 06:42
MHDA- 2023/09/05 06:41
CRDT- 2023/06/23 01:23
PHST- 2023/05/30 00:00 [revised]
PHST- 2023/04/26 00:00 [received]
PHST- 2023/06/13 00:00 [accepted]
PHST- 2023/09/05 06:41 [medline]
PHST- 2023/06/23 06:42 [pubmed]
PHST- 2023/06/23 01:23 [entrez]
AID - 10.1111/1744-9987.14028 [doi]
PST - ppublish
SO  - Ther Apher Dial. 2023 Oct;27(5):839-847. doi: 10.1111/1744-9987.14028. Epub 2023 
      Jun 22.